Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue.

Prostacyclin (PGI2), in a wide concentration range, produced neither contraction nor relaxation of isolated human saphenous vein. Isolated portal veins and vena cava from normal and spontaneously hypertensive rats (SHR) responded only with an increase in contractile tension when exposed to PGI2. This constrictor effect was absent in a calcium-free buffer. PGI2 failed to relax KCI contracted vena cava. The constrictor effect of PGI2 on portal vein was attenuated in a glucose-free, oxygen deficient buffer. No tachyphylaxis or tolerance to the constrictor effect of PGI2 was noted. Results emphasize that PGI2 may produce differing effects on vascular smooth muscle tension depending on species and type of blood vessel studied.     

Effects of prostacyclin (PGI2) and indomethacin on neonatal lamb mesenteric and renal artery responses to electrical stimulation and norepinephrine

The effects of prostacyclin (PGI₂) and indomethacin on isolated neonatal lamb mesenteric and renal artery responses to electrical stimulation and injected norepinephrine were investigated. PGI₂ (1μM) decreased baseline tension and significantly reduced vasoconstrictor responses to electrical stimulation and norepinephrine. Indomethacin raised baseline tension and potentiated the constrictor responses. PGI₂ reversed completely the potentiating effects of indomethacin. These results suggest that PGI₂ may modulate the responses to adrenergic stimuli in the mesenteric and renal arteries of neonatal lambs.     

Prostacyclin increases portal venous flow

Prostacyclin (PGI₂) is a potent vasolidator and is a potential therapeutic agent to increase blood flow during several disease states. PGI₂ is alos elevated in plasma during sepsis or pancreatitis. The hemodynamic effect of PGI₂ has not been investigated with regard to the portal venous system. In five anesthetized swine, cardiac output (CO), central venous pressure (CVP), femoral artery pressure (FAP), heart rate (HR), pulmonary artery pressure (PAP), portal venous flow (PoVF), and portal venous pressure (PoVP) were measured before and after increasing doses of PGI₂. The infusions were then repeated after atropine administration. The previously reported effects on the peripheral and pulmonary vascular systems were confirmed. after an injection of 0.5 to 5.0 ug/kg of PGI₂ into the left atrium, a significant decline in CO, FAP, and PAP occured. Atropinization further depressed CO. The most marked effecr of PGI₂, however, was an increase in PoVF without a change in PoVP. This effect was more pronounced when atropine was administered. In anethetized swine, PGI₂ is a potent vasodilator in all vascular beds, including the portal venous system. These hemodynamic changes should be realized when exogenous PGI₂ is considered as a therapeutic agent or when endogenous PGI₂ might increase in association with disease states like pancreatitis or sepsis.     

PGI2 production by rat blood vessels: Diminished prostacyclin formation in veins compared to arteries

Homogenates of eleven different blood vessels from normal Sprague-Dawley rats varied in their ability to produce PGI₂ (i.e., 6-keto-PGF_1α) from [1−¹⁴C]PGH₂. The most notable difference was seen between arteries and veins. Arterial tissues produced more 6-keto-PGF_1α from exogenous PGH₂ than veins at all enzyme (i.e., protein) concentrations tested. Similar results were obtained utilizing different homogenization techniques or arterial and venous rings, indicating this difference was real and not due to homogenization artifacts. In addition, the thoracic segment of the inferior vena cava was more active in converting added [1−¹⁴C]PGH₂ to 6-keto-PGF_1α than the abdominal segment of added inferior vena cava suggestive of a possible segmental distribution of the enzyme activity in blood vessels. These results may be interpreted as indicating that PGI₂ may have a vasomotor function for blood vessels in addition to its proposed antithrombotic role.     

A comparison of the pulmonary, renal and hepatic extractions of PGI2 and PGE2 - PGI2 a potential circulating hormone.

Prostaglandin (PG) I₂ and PGE₂ were infused into the aortic arch, femoral vein, renal artery and portal vein in anesthetized dogs over a dose range to produce a steady decrease in systemic blood pressure after 10 mins infusion. Parallel log dose-response relationships were observed with both PGI₂ and PGE₂. PGE₂ was a more potent depressor than PGI₂ when infused into the aortic arch. The doses to reduce blood pressure by 5 mm Hg were used to calculate the extraction of the compounds by the lungs, kidney and liver. The pulmonary extraction of PGE₂ was 96 ± 2% and was essentially complete following combined pulmonary and renal or pulmonary and hepatic extraction. In contrast, there was no significant pulmonary extraction of PGI₂. Combined renal and pulmonary extraction was 43 ± 11% and combined hepatic and pulmonary extraction 87 ± 5%. These results indicate a marked difference in the organ metabolising capacity for PGE₂ and PGI₂. Since PGI₂ has been shown to be produced both in the kidney and stomach it is possible that PGI₂ produced endogenously could pass into the circulation and exert systemic pharmacological effects.     

Involvement of the AT1 receptor in the venoconstriction induced by angiotensin II in both the inferior vena cava and femoral vein

Although angiotensin II-induced venoconstriction has been demonstrated in the rat vena cava and femoral vein, the angiotensin II receptor subtypes (AT₁ or AT₂) that mediate this phenomenon have not been precisely characterized. Therefore, the present study aimed to characterize the pharmacological receptors involved in the angiotensin II-induced constriction of rat venae cavae and femoral veins, as well as the opposing effects exerted by locally produced prostanoids and NO upon induction of these vasomotor responses. The obtained results suggest that both AT₁ and AT₂ angiotensin II receptors are expressed in both veins. Angiotensin II concentration-response curves were shifted toward the right by losartan but not by PD 123319 in both the vena cava and femoral vein. Moreover, it was observed that both 10⁻⁵ M indomethacin and 10⁻⁴ M L-NAME improve the angiotensin II responses in the vena cava and femoral vein. In conclusion, in the rat vena cava and femoral vein, angiotensin II stimulates AT₁ but not AT₂ to induce venoconstriction, which is blunted by vasodilator prostanoids and NO.     

Prostacyclin (PGI2) and U-46619 stimulate coronary arteries from diabetic dogs and their action is influenced by inhibitors of prostaglandin biosynthesis

Isolated coronary arteries from diabetic dogs presented different contractile response to U-46619 to prostacyclin (PGI₂) and to arachidonic acid (AA) than those of normal dogs. The stimulatory effect of the synthetic endoperoxide analogue U-46619, was significantly higher in the diabetic condition than in preparations from normal animals. On the other hand, while PGI₂ evoked a dose-dependent relaxation of normal coronary arteries, diabetic vessels were not relaxed by low concentration of PGI₂ whereas higher ones produced a distinct constrictor effect. Additionally, inhibitors of prostaglandins and thromboxane (TX) biosynthesis such as corticosterone, indomethacin, acetylsalicylic acid, imidazole and L-8027, abolished the stimulatory effect of PGI₂ in coronary arteries from diabetic dogs. AA relaxed coronaries from normal dogs and constricted those from diabetic animals, this action being inhibited by imidazol and L-8027.The present results suggests that: a) coronary vessels from diabetic dogs are more reactive to an endoperoxide analogue than normal preparations and b) PGI₂ and AA probably contract diabetic coronary arteries via the participation of a TX like material. It is then plausible that this effect could be tentatively ascribed to the production of a prostaglandin constricting substance including als the probable generation of a TXA₂-like agonist.     

Metabolism of PGI2 by 15-hydroxyprostaglandin-dehydrogenase and Δ13-reductase in different vascular beds of the cat in vivo

The metabolism of endogenous PGI₂ (released by angiotensin II or bradykinin) and exogenous PGI₂ by 15-hydroxy-PG-dehydrogenase and Δ¹³-reductase was studied in five different vascular beds of the anaesthetized cat. Plasma concentrations of 6-keto-PGF_1α (the product of spontaneous hydrolysis of PGI₂) and 6,15-diketo-13,14-dihydro-PGF_1α (the metabolite formed from PGI₂ by 15-hydroxy-PG-dehydrogenase and Δ¹³-reductase) were determined in the efferent vessels of the respective vascular beds by specific radioimmunoassays.No major metabolism of PGI₂ by 15-hydroxy-PG-dehydrogenase and Δ¹³-reductase was detected in the head and the hindlimbs of the cat. In the lung exogenous (circulating) PGI₂ was not metabolized, whereas PGI₂ synthetized in the lung itself was converted to 6,15-diketo-13,14-dihydor-PGF_1α. No significant amounts of 6,15-diketo-13,14-dihydro-PGF_1α-immunoreactivity were detected in hepatic venous blood after infusion of PGI₂ into the portal vein. However as also no 6-keto-PGF_1α was found, the liver seems to efficiently extract PGI₂ from the circulation. The cat kidney had the highest capacity of all vascular beds investigated to release endogenous and exogenous PGI₂ as 6-15-diketo-13,14-dihydro-PGF_1α. In other organs (vascular beds) investigated PGI₂ is either metabolized less efficiently by the 15-hydroxy-PG-dehydrogenase or further transformed to other metabolites.     

Stimulation of ovine myometrial activity by 6-keto prostaglandin E1

6-keto prostaglandin E₁ (6KE) is a metabolite of PGI₂, which we have shown previously inhibits spontaneous myometrial activity. In the present study we examined the effects of 6KE on uterine electrical and mechanical activity in non-pregnant ovariectomized sheep. 6KE stimulated uterine activity in a dose-dependent fashion. The effect was enhanced by pre-treatment with estradiol (E2). It was not influenced by pre-treatment with meclofenamic acid and was not associated with significant changes in the concentrations of 13,14 dihydro 15-keto PGF_2α in vena cava plasma. After E2 treatment, 6KE had 0.2–0.3 of the stimulatory activity of PGF_2α. In the absence of E2, the uterine response to both 6KE and PGF_2α was decreased. In animals in which spontaneous myometrial activity was inhibited by PGI2, the uterus remained responsive to 6KE. We conclude that in the ovariectomized non-pregnant sheep 6KE stimulates uterine activity, and that the effect is independent of endogenous PG production.     

A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney

A direct comparison of the relative potencies of the prostaglandins PGI₂ and 6-kto-PGE₁ to induce renin release was made in the isolated rat kidney, which was perfused with a synthetic medium at constant perfusion pressure.Both prostaglandins stimulated renin release in a dose-dependent manner (0.01 to 1 μM) and with equal potency.Also in the isolated rabbit kidney, PGI₂ and 6-keto-PGE₁ had the same potency to induce renin release at 1 μM final concentration.Following infusion of 6-keto-PGE₁ a small increase of vascular resistance in the rat kidney was observed, whereas in the rabbit kidney no constrictor effect was seen.When perfusate of PGI₂ or 6-keto-PGE₁-infused rat kidneys were tested for antiaggregatory activity in the ADP induced aggregation of human platelets and compared with authentic standards, the results showed 6-keto-PGE₁ passes the kidney essentially unchanged, whereas only 25–40% of the infused PGI₂ appear in the venous perfusates, as judged from the recovery of antiaggregatory activity.Analysis of venous perfusates from ³H-PGI₂ infused kidneys by high performance liquid chromatography indicates that about 25% of the infused PGI₂ remains intact, a major portion of the perfused radioactivity was identified as 6-keto-PGF_1α by combined gaschromatography-mass-spectrometry (19).We conclude that the renin-stimulating effect of PGI₂ is not secondary to its metabolism to 6-keto-PGE₁, as has been suggested in the literature (8).     

THE SURGICAL TREATMENT OF PORTAL HYPERTENSION

Portacaval shunt operations were done in 15 of 18 patients who were treated surgically for portal hypertension. In eight cases the shunt was established by splenorenal anastomosis; in seven by anastomosis of the portal vein to the side of the inferior vena cava. Of the eight patients with splenorenal shunt, two are well, four are considered improved, and two have died. Of the seven in whom the portal vein was joined to the vena cava, two are improved, one is unimproved, and four have died.     

Metabolism of PGI2 by 15-hydroxyprostaglandin-dehydrogenase and Δ-reductase in different vascular beds of the cat in vivo

The metabolism of endogenous PGI₂ (released by angiotensin II or bradykinin) and exogenous PGI₂ by 15-hydroxy-PG-dehydrogenase and Δ¹³-reductase was studied in five different vascular beds of the anaesthetized cat. Plasma concentrations of 6-keto-PGF_1α (the product of spontaneous hydrolysis of PGI₂) and 6,15-diketo-13,14-dihydro-PGF_1α (the metabolite formed from PGI₂ by 15-hydroxy-PG-dehydrogenase and Δ¹³-reductase) were determined in the efferent vessels of the respective vascular beds by specific radioimmunoassays.No major metabolism of PGI₂ by 15-hydroxy-PG-dehydrogenase and Δ¹³-reductase was detected in the head and the hindlimbs of the cat. In the lung exogenous (circulating) PGI₂ was not metabolized, whereas PGI₂ synthetized in the lung itself was converted to 6,15-diketo-13,14-dihydor-PGF_1α. No significant amounts of 6,15-diketo-13,14-dihydro-PGF_1α-immunoreactivity were detected in hepatic venous blood after infusion of PGI₂ into the portal vein. However as also no 6-keto-PGF_1α was found, the liver seems to efficiently extract PGI₂ from the circulation. The cat kidney had the highest capacity of all vascular beds investigated to release endogenous and exogenous PGI₂ as 6-15-diketo-13,14-dihydro-PGF_1α. In other organs (vascular beds) investigated PGI₂ is either metabolized less efficiently by the 15-hydroxy-PG-dehydrogenase or further transformed to other metabolites.     

The effects of a 5-lipoxygenase inhibitor, AA-861, on PGI2-like substance production in guinea-pig lungs

To determine the effects of AA-861 on PGI₂ production in guinea-pig lungs, 3 g of guinea-pig lung was chopped in 4 ml of buffer (control group), in buffer with 4 μg/ml indomethacin (indomethacin group) and in buffer with 2.5 × 10⁻⁵M AA-861 (AA-861 group). The chopped lungs were incubated for 30 min. 250 μl of incubation medium from each group was assessed before and after 3, 5, 10, 15, 20, 25 and 30 min of incubation. The incubation medium was centrifuged and the supernatant was tested for a PGI₂-like substance (PGI₂) by platelet aggregation inhibition. PGI₂ was produced mainly during the initial 3–5 min of incubation and was decreased thereafter. PGI₂ production was almost completely inhibited in the indomethacin group at all of the incubation times and was partially inhibited in the AA-861 group during the initial 3–5 minutes. Endogenous 5-lipoxygenase products generated in the early stages of incubation seem to be involved in PGI₂ production in guinea-pig lungs.     

Inhibitory effects of interleukin-6 on release of PGI2 by cultured human pulmonary artery smooth muscle cells

We evaluated the effect of interleukin-6 (IL-6) on the production of prostacyclin (PGI₂) by cultured human pulmonary artery smooth muscle cells (HPASMC). Incubation of these cells for up to 48 h with IL-6 led to a dose- and time-dependent decrease in the concentration of PGI₂ in the culture medium. The incubation of HPASMC with 10 μg/ml of lipopolysaccharide (LPS), 200 U/ml of IL-1β or 500 U/ml of TNFα for 24 hr significantly increased the concentration of PGI₂ in the medium. However, the addition of IL-6 to a medium containing LPS, IL-1β, or TNFα significantly inhibited the stimulatory effect of those substances on PGI₂ production. Such inhibition was closely related to the concentration of IL-6. IL-6 may counteract the roles of LPS and of other cytokines on the regulation of pulmonary vascular tension in endotoxin- and cytokine-mediated disorders such as sepsis and the acute respiratory distress syndrome (ARDS).     

Small bowel transplantation in mice

Since 1990, the development of tacrolimus-based immunosuppression and improved surgical techniques, the increased array of potent immunosuppressive medications, infection prophylaxis, and suitable patient selection helped improve actuarial graft and patient survival rates for all types of intestine transplantation. Patients with irreversible intestinal failure and complications of parenteral nutrition should now be routinely considered for small intestine transplantation. However, Survival rates for small intestinal transplantation have been slow to improve compares increasingly favorably with renal, liver, heart and lung. The small bowel transplantation is still unsatisfactory compared with other organs. Further progress may depend on better understanding of immunology and physiology of the graft and can be greatly facilitated by animal models. A wider use of mouse small bowel transplantation model is needed in the study of immunology and physiology of the transplantation gut as well as efficient methods in diagnosing early rejection. However, this model is limited to use because the techniques involved is an extremely technically challenging. We have developed a modified technique. When making anastomosis of portal vein and inferior vena cava, two stay sutures are made at the proximal apex and distal apex of the recipient s inferior vena cava with the donor s portal vein. The left wall of the inferior vena cava and donor s portal vein is closed with continuing sutures in the inside of the inferior vena cava after, after one knot with the proximal apex stay suture the right wall of the inferior vena cava and the donor s portal vein are closed with continuing sutures outside the inferior vena cave with 10-0 sutures. This method is easier to perform because anastomosis is made just on the one side of the inferior vena cava and 10-0 sutures is the right size to avoid bleeding and thrombosis. In this article, we provide details of the technique to supplement the video.     

Prostacyclin-induced contraction of isolated aortic strips from normal and spontaneously hypertensive rats (SHR)

Prostacyclin (PGl₂) (500-5,000 ng/ml) produced a concentration-dependent increase in contractile tension of isolated thoracic aortic strips (AS) from normotensive (WKY) and spontaneously hypertensive rats (SHR). No significant differences were noted between this response to PGl₂ in these two groups. Lower concentrations of PGl₂ (10 pg/ml — 100 ng/ml) caused neither contraction nor relaxation of agonist-contracted tissue. PGl₂ (500-5,000 ng/ml) did not relax KCl or methoxamine contracted AS. In concentrations above 100 ng/ml, PGl₂ caused a further increase in tension in KCl-depolarized preparations. The constrictor effect of PGl₂ on AS was attenuated by verapamil pretreatment or removal of extracellular Ca⁺⁺ from the physiological buffer. This inhibitory effect of Ca⁺⁺ deficiency on the PGl₂ response was significantly greater in AS from SHR compared to WKY tissue. The stable metabolite of PGl₂, 6-keto PGF_1a, caused a weak constrictor effect (40% of KCl reference contraction) over the concentration range 1,000–5,000 ng/ml. Contraction induced by PGl₂ was not prevented by pretreatment with antagonists of adrenergic, histamine, serotonin or cholinergic receptors. The contraction response of the rat AS to PGl₂ is similar to that reported for porcine coronary artery and rabbit aortic tissues in vitro.     

12-Hydroxyeicosatetraenoic acid reduces prostacyclin production by endothelial cells

12-Hydroxyeicosatetraenoic acid (12-HETE), a lipoxygenase product released by activated platelets and macrophages, reduced prostacyclin (PGI₂) formation in bovine aortic endothelial cultures by as much as 70%. Maximal inhibition required 1 to 2 h to occur and after 2 hr, a concentration of 1 μM 12-HETE produced 80% of the maximum inhibitory effect. 5-HETE and 15-HETE also inhibited PGI₂ formation. The inhibition was not specific for PGI₂; 12-HETE reduced the formation of all of the radioactive eicosanoids synthesized from [1-¹⁴C]arachidonic acid by human umbilical vein endothelial cultures. Inhibition occurred in the human cultures when PGI₂ formation was elicited with arachidonic acid, ionophore A23187 or thrombin. These findings suggest that prolonged exposure to HETEs may compromise the antithrombotic and vasodilator properties of the endothelium by reducing its capacity to produce eicosanoids, including PGI₂.     

Agonist specific desensitization of leukotriene C4-stimulated PGI2 biosynthesis in human endothelial cells

Leukotriene C₄ (LTC₄) and, to a lesser extent, leukotriene D₄ (LTD₄) concentration dependently stimulate prostacyclin (PGI₂) biosynthesis in cultured human umbilical vein endothelial cells. PGI₂ biosynthesis was quantitated by radioimmunoassay and its structure confirmed by gas chromatography/mass spectrometry. Preincubation of endothelial cells with LTC₄ resulted in desensitization to subsequent LTC₄ stimulation. However, PGI₂ biosynthesis in response to thrombin, PGH₂ and arachidonic acid was not inhibited by preincubation with LTC₄. The C-6-sulfidopeptide leukotriene receptor level antagonist FPL-55712 attenuates LTC₄, but not thrombin-stimulated PGI₂ biosynthesis. These data suggest that human umbilical vein endothelial cells have a C-6-sulfidopeptide leukotriene receptor, and that stimulation of this receptor results in PGI₂ biosynthesis.     

Simultaneous collection of the portal and superior vena cava blood in conscious rats defined that intestinal epithelium is the major site of glucuronidation,but not sulfation and methylation,of quercetin

ABSTRACT

Quercetin is a flavonoid with many physiological effects. Absorbed quercetin is rapidly conjugated in the intestinal epithelium and liver. Different positional isomers of quercetin conjugates have different physiological properties. However, the mechanisms of quercetin conjugation in the intestine are not fully clarified. We examined the regioselective quercetin conjugate formation in the intestine after oral administration of quercetin glycosides, by simultaneous sampling of blood from the portal vein and superior vena cava, and quantifying various positional isomers of quercetin glucuronides and sulfates in conscious rats. Concentrations of quercetin glucuronides were higher in blood from the portal vein than the superior vena cava, showing that glucuronidation mainly occurred in the intestine. Such differences were not observed for quercetin sulfates. Regioselectivity of the intestinal glucuronidation in quercetin hydroxyl groups were 7- >3′- >3- >4′-OH. Quercetin was mainly sulfated on 3′-OH at 30 min, but on 4′-OH at 240 min.     

Chronic utero-ovarian vein catheterization with subsequent occlusion prolongs the estrous cycle and changes electromyographic activity in the myometrium of ewes

The objective of our study was to determine the effect of chronic utero-ovarian vein catheterization in ewes on estrous cycle length, plasma progesterone (P) concentration, and myometrial electromyographic activity. Cyclic ewes with inferior vena cava catheters were used as controls. Estrus was synchronized in ten ewes and 10 to 12 d following estrus, the ewes were anesthetized, fitted with myometrial electromyograph leads and with utero-ovarian vein (n = 5) or inferior vena cava (n = 5) catheters. After surgery, ewes returned to estrus as expected (16 to 18 d interestrus interval). The second cycle of four of five ewes with utero-ovarian vein catheters were prolonged (40 to 58 d). The inferior vena cava catheterized ewes had normal length second cycles. Plasma P concentrations reflected the estrous cycles: low ( 0.05).